Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group

Leukemia Research

Volumn 54, Issue , 2017, Pages 55-58

  Iriyama, Noriyoshi ^a   Tokuhira, Michihide ^b   Takaku, Tomoiku ^c   Sato, Eriko ^d   Ishikawa, Maho ^e   Nakazato, Tomonori ^f   Sugimoto, Kei Ji ^g   Fujita, Hiroyuki ^h   Fujioka, Isao ^c   Hatta, Yoshihiro ^a   Kizaki, Masahiro ^b   Komatsu, Norio ^c   Asou, Norio ^e   Kawaguchi, Tatsuya ⁱ  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^g JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^h Saiseikai Yokohama Nanbu Hospital   (Japan)

ⁱ KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Prognosis; Therapy related chronic myeloid leukemia; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; HEMOGLOBIN; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; SEX DIFFERENCE; THERAPY RELATED CHRONIC MYELOID LEUKEMIA; THROMBOCYTE COUNT; TIME TO TREATMENT; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; DASATINIB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMATINIB MESYLATE; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85009904468     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2017.01.003     Document Type: Article

References (25)

1. [1] Aguiar, R.C., Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk. Lymphoma 29 (1998), 17–26.
2. [2] Kantarjian, H., O'Brien, S., Jabbour, E., Shan, J., Ravandi, F., Kadia, T., et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J. Clin. Oncol. 29 (2011), 3173–3178.
3. [3] Tauchi, T., Kizaki, M., Okamoto, S., Tanaka, H., Tanimoto, M., Inokuchi, K., et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk. Res. 35 (2011), 585–590.
4. [4] Saglio, G., Kim, D.W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362 (2010), 2251–2259.
5. [5] Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362 (2010), 2260–2270.
6. [6] Ramanarayanan, J., Dunford, L.M., Baer, M.R., Sait, S.N., Lawrence, W., McCarthy, P.L., Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk. Res. 30 (2006), 701–705.
7. [7] Lee, H.Y., Lee, K.H., Hyun, M.S., Kim, M.K., Koh, S.A., Cho, H.S., Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma. Korean J. Intern. Med. 29 (2014), 250–252.
8. [8] Higuchi, M., Nishinaka, H., Yamano, Y., A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer. Gan To Kagaku Ryoho 33 (2006), 2049–2052.
9. [9] Shibazaki, M., Sumi, M., Takeda, W., Kirihara, T., Kurihara, T., Sato, K., et al. Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma. Rinsho Ketsueki 55 (2014), 970–974.
10. [10] Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122 (2013), 872–884.
11. [11] Iriyama, N., Fujisawa, S., Yoshida, C., Wakita, H., Chiba, S., Okamoto, S., et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML Study Group. Am. J. Hematol. 90 (2015), 282–287.
12. [12] Cross, N.C., White, H.E., Muller, M.C., Saglio, G., Hochhaus, A., Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26 (2012), 2172–2175.
13. [13] Yagasaki, F., Niwa, T., Abe, A., Ishikawa, M., Kato, C., Ogura, K., et al. Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki 50 (2009), 481–487.
14. [14] Iriyama, N., Hatta, Y., Kobayashi, S., Uchino, Y., Miura, K., Kurita, D., et al. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia. Int. J. Hematol. 100 (2014), 379–385.
15. [15] Kanda, Y., Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transplant. 48 (2013), 452–458.
16. [16] Granfeldt Ostgard, L.S., Medeiros, B.C., Sengelov, H., Norgaard, M., Andersen, M.K., et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study. J. Clin. Oncol. 33 (2015), 3641–3649.
17. [17] Azam, M., Latek, R.R., Daley, G.Q., Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003), 831–843.
18. [18] Itonaga, H., Tsushima, H., Imanishi, D., Hata, T., Doi, Y., Mori, S., et al. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group. Leuk. Res. 38 (2014), 76–83.
19. [19] Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., Talpaz, M., BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003), 690–698.
20. [20] Mahon, F.X., Hayette, S., Lagarde, V., Belloc, F., Turcq, B., Nicolini, F., et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 68 (2008), 9809–9816.
21. [21] Makishima, H., Jankowska, A.M., McDevitt, M.A., O'Keefe, C., Dujardin, S., Cazzolli, H., et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 117 (2011), e198–206.
22. [22] Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371 (2014), 2488–2498.
23. [23] Schmidt, M., Rinke, J., Schafer, V., Schnittger, S., Kohlmann, A., Obstfelder, E., et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 28 (2014), 2292–2299.
24. [24] Kamada, N., Tanaka, K., Oguma, N., Mabuchi, K., Cytogenetic and molecular changes in leukemia among atomic bomb survivors. J. Radiat. Res. 32 (1991), 257–265.
25. [25] Ichimaru, M., Tomonaga, M., Amenomori, T., Matsuo, T., Atomic bomb and leukemia. J. Radiat. Res. 32 (1991), 14–19.